Trading Signals: MDT Stock Price Prediction and Forecast (Mon. Mar. 17, 2014 - Wed. Sep. 27, 2023)(Medtronic plc)
| MDT latest price $126.5900 (1.15%) ($126.3300 - $128.0500) on Sat. May. 29, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 0.99% (three month average) | RSI | 48 | Latest Price | $126.5900(1.15%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | MDT declines -0.1% a day on average for past five trading days. | Weekly Trend | MDT advances 0.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support MDT advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting MDT price | MDT will decline at least -0.495% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -0.495% (StdDev 0.99%) | Hourly BBV | 0 () | Intraday Trend | -0% | | | |
|
5 Day Moving Average | $126.9(-0.24%) | 10 Day Moving Average | $126.57(0.02%) | 20 Day Moving Average | $126.52(0.06%) | To recent high | -3.7% | To recent low | 10% | Market Cap | $N/A | | | | Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland. |